03:52 PM EST - Acasti Pharma : reports the highlights of its financial results for the second quarter, ended August 31, 2012. During the three-month period ended August 31, 2012 Acasti generated revenues of $237,000 from sales of Onemia, while Acasti did not generate revenues from sales during the corresponding period of 2011. Net loss amounted to $1,752,000, or $0.02 per share for the three-month period ended August 31, 2012 compared to $1,724,000, or $0.03 per share, for the corresponding period of 2011. Acasti Pharma
shares V.APO are trading unchanged at $2.10.
